Locke Bryan, PhD, Medical Hematologist ...

Dr. Locke J. Bryan

Claim this profile

Augusta University Medical Center

Studies Lymphoma
Studies Follicular Lymphoma
9 reported clinical trials
20 drugs studied

Area of expertise

1Lymphoma
Locke J. Bryan has run 5 trials for Lymphoma. Some of their research focus areas include:
Stage III
Stage IV
MYC positive
2Follicular Lymphoma
Locke J. Bryan has run 4 trials for Follicular Lymphoma. Some of their research focus areas include:
MYC positive
BCL2 positive
BCL6 positive

Affiliated Hospitals

Image of trial facility.
Augusta University Medical Center
Image of trial facility.
Georgia Cancer Center

Clinical Trials Locke J. Bryan is currently running

Image of trial facility.

Rituximab vs Mosunetuzumab

for Follicular Lymphoma

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.
Recruiting2 awards Phase 313 criteria
Image of trial facility.

Zanubrutinib

for Mantle Cell Lymphoma

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used in MCL, the current standard of care is to continue administering the drug indefinitely until disease progression. This continuous treatment comes with clinical as well as financial toxicity, which could be especially detrimental in older patients. For patients who achieve a CR after initial zanubrutinib plus rituximab therapy, it may be safe and equally effective to stop treatment and restart zanubrutinib upon disease progression rather than continuing indefinitely in previously untreated older adult patients with MCL.
Recruiting2 awards Phase 310 criteria

More about Locke J. Bryan

Clinical Trial Related6 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Locke J. Bryan has experience with
  • Rituximab
  • Ibrutinib
  • Autologous Hematopoietic Stem Cell Transplantation
  • IMPT-314
  • L-Bcl-2 Antisense Oligonucleotide
  • Venetoclax

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Locke J. Bryan specialize in?
Is Locke J. Bryan currently recruiting for clinical trials?
Are there any treatments that Locke J. Bryan has studied deeply?
What is the best way to schedule an appointment with Locke J. Bryan?
What is the office address of Locke J. Bryan?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security